Kiwi thanks for taking the time to write your thoughts on these two stocks. I imagine the p value in the pediatric study was positive even though the sample size was small. I did find some info about the FDA funding for it: "SCD-PED-01 was funded primarily by an Office of Orphan Products Development (OOPD) grant (R01FD005092) from the US FDA with a small subsequent grant from SeaStar Medical Inc to complete the final 2 participants’ enrollment. SCD-PED-02 was funded by the Frankel Innovation Initiative at the University of Michigan. None of the aforementioned sponsors had any role in study design, collection, analysis, and interpretation of data, writing the report, or the decision to submit the report for publication"https://www.sciencedirect.com/science/article/pii/S2590059524000037
Also, it must not be terribly easy to enroll patients who are on their deathbed. Or maybe it is, not sure how that situation is handled.